The Speculator (David Haselhurst) in today's Bulletin magazine has picked VLA as a strong buy recommendation.
The write-up is exceptionally robust by Haselhurst's normal standards.
(Can't give you a link - it isn't on the Internet yet. However the mag has just hit the newsstands.)
As a one-time medical writer/researcher, I can verify that novel cancer-fighting technologies are thin on the ground. VLA's has much promise.
Haselhurst points out (correctly IMO) that this is a sitting duck for a takeover right now, and one of the big pharmaceutical companies could snap it up "out of the petty cash tin".
With VLA still so cheap and its product looking strong (with new results round the corner), this seems to me a fairly strong buy right now.